Cargando…

Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern

In order to detect the SARS-CoV-2 variants of concern (VOCs), five real-time reverse transcriptase PCR (rRT-PCR) assays were designed to target the critical discriminatory mutations responsible for the following amino acid changes in the spike protein: two Δ69–70 + N501Y + E gene triplexes (one opti...

Descripción completa

Detalles Bibliográficos
Autores principales: Pabbaraju, Kanti, Zelyas, Nathan, Wong, Anita, Croxen, Matthew A., Lynch, Tarah, Buss, Emily, Murphy, Stephanie, Shokoples, Sandy, Kanji, Jamil, Tipples, Graham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134755/
https://www.ncbi.nlm.nih.gov/pubmed/35644262
http://dx.doi.org/10.1016/j.jviromet.2022.114553
_version_ 1784713825015037952
author Pabbaraju, Kanti
Zelyas, Nathan
Wong, Anita
Croxen, Matthew A.
Lynch, Tarah
Buss, Emily
Murphy, Stephanie
Shokoples, Sandy
Kanji, Jamil
Tipples, Graham
author_facet Pabbaraju, Kanti
Zelyas, Nathan
Wong, Anita
Croxen, Matthew A.
Lynch, Tarah
Buss, Emily
Murphy, Stephanie
Shokoples, Sandy
Kanji, Jamil
Tipples, Graham
author_sort Pabbaraju, Kanti
collection PubMed
description In order to detect the SARS-CoV-2 variants of concern (VOCs), five real-time reverse transcriptase PCR (rRT-PCR) assays were designed to target the critical discriminatory mutations responsible for the following amino acid changes in the spike protein: two Δ69–70 + N501Y + E gene triplexes (one optimized for Alpha [B.1.1.7] and one optimized for Omicron [B.1.1.529]), a K417N + 242–244 wild-type duplex, a K417T + E484K duplex, and a L452R + P681 + E484Q triplex. Depending on the assay, sensitivity was 98.97–100% for the detection of known VOC-positive samples, specificity was 97.2–100%, limit of detection was 2–116 copies/reaction, intra- and interassay variability was less than 5%, and no cross-reactivity with common respiratory pathogens was observed with any assay. A subset of rRT-PCR- positive VOC samples were further characterized by genome sequencing. A comparison of the lineage designation by the VOC rRT-PCR assays and genome sequencing for the detection of the Alpha, Beta, Gamma, Delta and Omicron variants showed clinical sensitivities of 99.97–100 %, clinical specificities of 99.6–100 %, positive predictive values of 99.8–100%, and negative predictive values of 99.98–100 %. We have implemented these rRT-PCR assays targeting discriminatory single nucleotide polymorphisms for ongoing VOC screening of SARS-CoV-2 positive samples for surveillance purposes. This has proven extremely useful in providing close to real-time molecular surveillance to monitor the emergence of Alpha, the replacement of Alpha by Delta, and the replacement of Delta by Omicron. While the design, validation and implementation of the variant specific PCR targets is an ever-evolving approach, we find the turn-around-time, high throughput and sensitivity to be a useful complementary approach for SARS-CoV-2 genome sequencing for surveillance purposes in the province of Alberta, Canada.
format Online
Article
Text
id pubmed-9134755
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-91347552022-05-26 Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern Pabbaraju, Kanti Zelyas, Nathan Wong, Anita Croxen, Matthew A. Lynch, Tarah Buss, Emily Murphy, Stephanie Shokoples, Sandy Kanji, Jamil Tipples, Graham J Virol Methods Article In order to detect the SARS-CoV-2 variants of concern (VOCs), five real-time reverse transcriptase PCR (rRT-PCR) assays were designed to target the critical discriminatory mutations responsible for the following amino acid changes in the spike protein: two Δ69–70 + N501Y + E gene triplexes (one optimized for Alpha [B.1.1.7] and one optimized for Omicron [B.1.1.529]), a K417N + 242–244 wild-type duplex, a K417T + E484K duplex, and a L452R + P681 + E484Q triplex. Depending on the assay, sensitivity was 98.97–100% for the detection of known VOC-positive samples, specificity was 97.2–100%, limit of detection was 2–116 copies/reaction, intra- and interassay variability was less than 5%, and no cross-reactivity with common respiratory pathogens was observed with any assay. A subset of rRT-PCR- positive VOC samples were further characterized by genome sequencing. A comparison of the lineage designation by the VOC rRT-PCR assays and genome sequencing for the detection of the Alpha, Beta, Gamma, Delta and Omicron variants showed clinical sensitivities of 99.97–100 %, clinical specificities of 99.6–100 %, positive predictive values of 99.8–100%, and negative predictive values of 99.98–100 %. We have implemented these rRT-PCR assays targeting discriminatory single nucleotide polymorphisms for ongoing VOC screening of SARS-CoV-2 positive samples for surveillance purposes. This has proven extremely useful in providing close to real-time molecular surveillance to monitor the emergence of Alpha, the replacement of Alpha by Delta, and the replacement of Delta by Omicron. While the design, validation and implementation of the variant specific PCR targets is an ever-evolving approach, we find the turn-around-time, high throughput and sensitivity to be a useful complementary approach for SARS-CoV-2 genome sequencing for surveillance purposes in the province of Alberta, Canada. Published by Elsevier B.V. 2022-09 2022-05-26 /pmc/articles/PMC9134755/ /pubmed/35644262 http://dx.doi.org/10.1016/j.jviromet.2022.114553 Text en © 2022 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pabbaraju, Kanti
Zelyas, Nathan
Wong, Anita
Croxen, Matthew A.
Lynch, Tarah
Buss, Emily
Murphy, Stephanie
Shokoples, Sandy
Kanji, Jamil
Tipples, Graham
Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern
title Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern
title_full Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern
title_fullStr Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern
title_full_unstemmed Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern
title_short Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern
title_sort evolving strategy for an evolving virus: development of real-time pcr assays for detecting all sars-cov-2 variants of concern
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134755/
https://www.ncbi.nlm.nih.gov/pubmed/35644262
http://dx.doi.org/10.1016/j.jviromet.2022.114553
work_keys_str_mv AT pabbarajukanti evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern
AT zelyasnathan evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern
AT wonganita evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern
AT croxenmatthewa evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern
AT lynchtarah evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern
AT bussemily evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern
AT murphystephanie evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern
AT shokoplessandy evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern
AT kanjijamil evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern
AT tipplesgraham evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern